TX-FLUENCE
2.2.2023 14:31:43 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005215/en/
Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire)
Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them.
Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received a medical cannabis license from the Portuguese government. The company is focused on delivering premium quality medicinal cannabis products that adhere to the Good Agricultural and Collection Practice (GACP) and Good Distribution Practices (GDP) wholesale standards, along with all relevant Portuguese regulations.
As a fully indoor facility dedicated to research and development, Key Leaves depends on sole-source lighting for its success—completing more than 20 full cultivation cycles using Fluence LED technology. Fluence’s LEDs have helped Key Leaves optimize production and cultivation light cycles, increase plant yield, uniformity and decrease energy consumption.
“To achieve our business objectives using the most effective and efficient production processes possible, we’ve invested in the world-class technologies and partnerships available,” said Alessandro Radici, CEO at Key Leaves. “Fluence’s market-leading LED technology and the on-call support of its research and horticulture teams allow us to cultivate with maximum efficacy, deliver a highly standardized product and guarantee constant supply for our clients.”
Fluence provides LED lighting solutions to 10 other licensed Portuguese medical cannabis producers—including Bathera, Curaleaf International and Clever Leaves, and pre-licensed AceCann—as well as several additional companies that are currently seeking licensing. Bathera, a German company, recently began producing its own medical cannabis and decided to construct its indoor cultivation and manufacturing facility near Lisbon. The site, currently in progress, houses 6,000 square meters of rooms dedicated to cultivation and 3,000 square meters of space for supporting areas, such as a GMP zone, six drying rooms and space for hand trimming and manual packaging.
“Because of the great Portuguese weather, outdoor cultivation is, of course, possible. We performed rigorous research and analysis with every construction decision and, after looking at the various options, we decided that cultivating indoors is the only way to ensure stable, high-quality products,” said Boris Agababov, founder and CEO of Bathera.
Curaleaf International focuses on advancing the therapeutic value of cannabis used for medicinal purposes to develop products that meet the needs of patients across Europe. The company’s commitment to accessibility, research and data-led product excellence brought it to Fluence when a lighting partner was needed for its Portuguese operations.
“Fluence’s goal is to help our customers grow smarter and build efficient economies of scale,” said Jörg Meyer-Brenken, lead account manager of cannabis in EMEA at Fluence. “We are led by science, and the collaborative approach we take to provide our partners with tailored lighting solutions, knowledge and experience has proven irreplaceable, especially for those in emerging medicinal cannabis markets.”
Portuguese native André Lagareiro, Fluence’s dedicated account manager for Portugal, works closely with Fluence’s Portuguese customers to help them identify the right lighting solutions to optimize plant growth and facility operations.
“Helping companies to innovate and advance medical cannabis operations within Portugal’s legislative environment requires a deep understanding of both cannabis cultivation and European regulatory standards,” said Lagareiro. “The unmatched top-of-the-line product, market expertise and quality of service provided by Fluence’s in-house research and development team is the deciding factor for the many Portuguese cannabis companies that have chosen Fluence as their lighting technology partner.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About AceCann
AceCann is a Portuguese medical cannabis company that has a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon. AceCann is focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities and operating on a flexible structure capable of making fast decisions to scale according to market demands and needs.
About Key Leaves
Key Leaves is a Portuguese-founded company established in 2015 and licensed by Infarmed for the cultivation, import and export of cannabis products. With a multicultural and diversified international team, Key Leaves is proud to be working with some of the most renowned professionals and experts in the medicinal cannabis field.
About Bathera
Bathera is a vertically integrated medical cannabis company with operations in Germany and Portugal. In addition to its state of the art indoor medical cannabis growing facility in Portugal, Bathera, operates two independent wholesalers and importers for medical cannabis in Germany.
About Curaleaf
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021. For more information about Curaleaf International, please visit www.curaleafinternational.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom